KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Idexx Laboratories (IDXX) Research & Development (2016 - 2025)

Historic Research & Development for Idexx Laboratories (IDXX) over the last 17 years, with Q3 2025 value amounting to $63.4 million.

  • Idexx Laboratories' Research & Development rose 1748.3% to $63.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $242.1 million, marking a year-over-year increase of 1319.84%. This contributed to the annual value of $219.8 million for FY2024, which is 1510.39% up from last year.
  • Per Idexx Laboratories' latest filing, its Research & Development stood at $63.4 million for Q3 2025, which was up 1748.3% from $61.9 million recorded in Q2 2025.
  • Over the past 5 years, Idexx Laboratories' Research & Development peaked at $123.2 million during Q2 2022, and registered a low of $37.6 million during Q1 2021.
  • Over the past 5 years, Idexx Laboratories' median Research & Development value was $48.0 million (recorded in 2022), while the average stood at $53.2 million.
  • Its Research & Development has fluctuated over the past 5 years, first skyrocketed by 22687.22% in 2022, then crashed by 6225.89% in 2023.
  • Idexx Laboratories' Research & Development (Quarter) stood at $45.3 million in 2021, then decreased by 4.17% to $43.4 million in 2022, then increased by 19.33% to $51.8 million in 2023, then rose by 11.42% to $57.7 million in 2024, then increased by 9.85% to $63.4 million in 2025.
  • Its Research & Development stands at $63.4 million for Q3 2025, versus $61.9 million for Q2 2025 and $59.1 million for Q1 2025.